MS Patients Reduce Use Of Opioids, Benzodiazepines Following Initiation Of Cannabis Therapy

opioids marijuana cannabis

The use of cannabis is associated with symptom mitigation and the reduced consumption of prescription drugs in patients with multiple sclerosis, according to data published in the journal Neurology.

A team of investigators from the DENT Neurologic Institute in New York performed a retrospective chart review of 77 MS patients undergoing treatment with medical cannabis. The majority of subjects reported reductions in pain, and nearly half reported improvements in spasticity and sleep. “In addition, 34 percent of patients were able to decrease or discontinue other medications, including opioids, stimulants, and benzodiazepines, indicative of symptom improvement.”

Authors concluded, “Patients with multiple sclerosis who initiated medical cannabis treatment experienced improved symptomology with good tolerability and were able to decrease or altogether discontinue opioids, stimulants and benzodiazepines.”

Their findings are consistent with those of other studies reporting the reduced use of opioids and other prescription drugs following patients’ initiation of cannabis therapy.

A marijuana plant-derived oral extract drug, Sativex, is approved for the treatment of MS-related spasticity in a number of countries, including Canada and the United Kingdom.

Source: NORMLmake a donation

Johnny Green
About Johnny Green 2493 Articles
Johnny Green is a cannabis activist from Oregon. Johnny has a bachelor's degree in public policy, and believes that the message should always be more important than the messenger. #LegalizeIt #FreeThePlant